Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Axitinib
Drug ID BADD_D00193
Description Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3).[L6676] Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors.[L6676] Axitinib is an indazole derivative.[A179398] It is most commonly marketed under the name Inlyta® and is available in oral formulations.
Indications and Usage Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.
Marketing Status approved; investigational
ATC Code L01EK01
DrugBank ID DB06626
KEGG ID D03218
MeSH ID D000077784
PubChem ID 6450551
TTD Drug ID D01ZRI
NDC Product Code 0069-0145; 54893-0032; 68554-0088; 63539-026; 82920-028; 0069-0151; 65344-0033; 63539-044; 54893-0043
UNII C9LVQ0YUXG
Synonyms Axitinib | AG 013736 | AG013736 | AG-013736 | Inlyta
Chemical Information
Molecular Formula C22H18N4OS
CAS Registry Number 319460-85-0
SMILES CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)C=CC4=CC=CC=N4
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pneumothorax spontaneous22.05.02.0070.000112%Not Available
Renal cancer stage IV20.01.04.014; 16.08.02.0080.000358%Not Available
Renal cell carcinoma stage IV20.01.04.016; 16.08.02.0100.000302%Not Available
Tumour embolism24.01.01.034; 16.32.03.0300.000168%Not Available
Urinary bladder haemorrhage24.07.01.086; 20.03.01.0230.000112%Not Available
Renal cancer metastatic20.01.04.012; 16.08.02.0060.002026%Not Available
Pulmonary cavitation22.01.02.0220.000112%Not Available
Lymphangiosis carcinomatosa24.09.02.007; 16.22.02.009; 01.09.01.0270.000112%Not Available
Postrenal failure20.01.03.0210.000112%Not Available
Malignant urinary tract neoplasm20.08.01.005; 16.08.04.0010.001713%Not Available
Spinal cord neoplasm17.20.01.009; 16.30.01.0090.000112%Not Available
Stress cardiomyopathy24.04.04.026; 02.04.01.0120.000168%Not Available
Exposed bone in jaw15.02.04.0340.000246%Not Available
Spinal pain17.10.01.020; 15.02.01.008; 08.01.08.0300.000302%Not Available
Clear cell renal cell carcinoma20.01.04.008; 16.08.02.0040.000828%Not Available
Diabetic metabolic decompensation14.07.03.003; 05.07.03.003--Not Available
Internal haemorrhage24.07.01.0720.000280%Not Available
End stage renal disease20.01.03.0190.000224%Not Available
Tongue discomfort07.14.02.0190.001007%Not Available
Cardiac dysfunction02.11.01.0040.000168%Not Available
Gait inability17.02.05.069; 08.01.02.0110.001623%Not Available
Hyperaesthesia teeth07.09.06.0050.000437%Not Available
Illness08.01.03.0910.003414%Not Available
Immune thrombocytopenia10.02.01.083; 01.08.01.0130.000112%Not Available
Immune-mediated hepatitis10.02.01.085; 09.01.07.037--Not Available
Pharyngeal swelling22.04.05.0280.000302%Not Available
Physical deconditioning08.01.03.096--Not Available
Sensitive skin23.03.03.0970.000112%Not Available
Sleep deficit17.15.04.0100.000381%Not Available
Taste disorder17.02.07.029; 07.14.03.0040.002574%Not Available
The 16th Page    First    Pre   16 17    Next   Last    Total 17 Pages